Welcome to our dedicated page for Cvs Health SEC filings (Ticker: CVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CVS Health’s integrated model—retail pharmacies, a leading PBM and a major insurer—produces sprawling SEC documents that mix drug-pricing mechanics with insurance risk metrics. Finding where opioid litigation reserves sit in a 10-K or tracking when executives sell shares before material announcements can feel impossible.
Stock Titan solves that complexity. Our AI reads every page the moment a filing hits EDGAR, then serves concise answers to the questions investors actually ask, like “CVS Health SEC filings explained simply” or “How do I read the CVS Health annual report 10-K simplified?”. You’ll see segment revenue, prescription volume trends, and medical loss ratios flagged automatically, alongside plain-language guidance for each section.
All filing types appear in one place and update in real time:
- CVS Health quarterly earnings report 10-Q filing with side-by-side KPI charts
- CVS Health 8-K material events explained within minutes of release
- CVS Health proxy statement executive compensation tables parsed and summarized
- CVS Health insider trading Form 4 transactions streamed live, plus alerts for CVS Health executive stock transactions Form 4
Need deeper context? Click “AI Review” for CVS Health earnings report filing analysis or use the search bar for “understanding CVS Health SEC documents with AI.” Whether you’re modelling PBM margins, monitoring CVS Health Form 4 insider transactions real-time, or benchmarking cash flows, our expert narratives replace hours of manual reading with insights you can act on immediately.
CVS Health’s Q2-25 10-Q shows top-line strength but margin pressure. Total revenue rose 8.4% YoY to $98.9 bn on higher pharmacy volumes (+9% Pharmacy & Consumer Wellness) and PBM growth (+10% Health Services). Six-month revenue is up 7.7% to $193.5 bn.
Profitability weakened. Q2 operating income fell 22% to $2.38 bn and net income attributable to CVS dropped 42% to $1.02 bn; diluted EPS slid to $0.80 (vs $1.41). For the first half, EPS declined 3% to $2.21, reflecting cost inflation, $448 mn premium deficiency on individual exchange products (recorded Q1) and an additional $471 mn reserve for Group Medicare Advantage in Q2. The Health Services unit also booked $288 mn of losses tied to exiting ACO REACH and selling its MSSP operations (including a $236 mn loss on divestiture).
Cash & balance sheet. Operating cash flow fell to $6.45 bn (-19% YoY). Cash & equivalents climbed to $11.8 bn (from $8.6 bn) aided by lower CapEx and debt repayments ($0.8 bn repaid; no new long-term debt issued). Net debt fell ~2 %, while equity rose to $77.4 bn. No share buybacks YTD; dividends of $0.665 per share continue.
Management confirms four-segment structure and notes planned exit from ACA individual exchanges by Jan-26. 1.268 bn shares were outstanding at 7/23/25.
COMPASS Pathways plc (Nasdaq: CMPS) filed its Q2-25 Form 10-Q. The clinical-stage biotech remains pre-revenue and focuses on COMP360 psilocybin for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD).
- Phase 3 progress: Trial COMP005 (n=258) hit its primary MADRS endpoint (p<0.001; −3.6 vs placebo) with top-line 6-week data; 26-week read-outs will follow COMP006 Part A completion (H2-26).
- Operating results: Q2 net loss widened slightly to $38.4 m (-$0.41/sh) versus $38.1 m prior-year; six-month loss narrowed to $56.3 m from $73.3 m as G&A fell 12% and R&D rose 13%.
- Cash position: Cash & equivalents rose to $221.9 m (31 Dec-24: $165.1 m) after a $149.8 m January equity/warrant financing and $140.5 m H1 financing cash inflow. Management projects runway into 2027.
- Balance sheet: Warrant liabilities introduced at $74.4 m; total debt $31.0 m under Hercules loan (14.8% EIR) with $22.5 m minimum-cash covenant. Share count expanded to 95.9 m ADS equivalents.
- Cash flow: H1 operating cash burn $84.3 m offset by $140.5 m financing inflow; cap-ex immaterial.
Outlook: Key near-term catalysts are FDA dialogue on COMP005 data and continued enrollment of COMP006. Management is designing a late-stage PTSD program. Despite ample cash, future dilution risk persists via 35.1 m outstanding pre-funded & 2025 ADS warrants and $122 m of PIPE warrants.
FAQ
What is the current stock price of Cvs Health (CVS)?
What is the market cap of Cvs Health (CVS)?
What are the core business segments of CVS Health?
How does CVS Health integrate its services?
What role does digital technology play at CVS Health?
How does CVS Health differentiate itself from other healthcare providers?
What is the significance of CVS Health’s pharmacy benefits management?
How does CVS Health support community health?
What types of health insurance products does CVS Health offer?
Why is CVS Health considered a trusted healthcare partner?
